Sommaire

Numéro précédent | Numéro suivant

• • ·Index

    Page :5A

    
• • ·Dealing with success at the American Heart Journal

    Page :769

    Robert M. Califf, Daniel B. Mark

    
• • ·Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era

    Page :770-773

    Hanno L. Tan, Kong I. Lie

    
• • ·Coronary artery calcification: “...empty your cup...”

    Page :774-776

    John A. Rumberger

    
• • ·Diastolic dysfunction: Old dog, new tricks

    Page :777-778

    Pamela S. Douglas

    
• • ·Natural disaster plus wake-up time: A deadly combination of triggers

    Page :779-781

    Robert A. Kloner, Jonathan Leor

    
• • ·Lung thallium imaging in coronary transplant arteriopathy: “Ce n’est pas un pipe”

    Page :782-785

    D.Douglas Miller

    Plan Plan
• • ·Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial

    Page :786-791

    Frans Van de Werf, Christopher P. Cannon, Anne Luyten, Katrijn Houbracken, Carolyn H. McCabe, Silvano Berioli, Erich Bluhmki, Hans Sarelin, Fong Wang-Clow, Norma Lynn Fox, Eugene Braunwald, For the ASSENT-1 investigators*

    Résumé Résumé Plan Plan
• • ·Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction

    Page :792-798

    Zygmunt P. Sadowski, John H. Alexander, Bogdan Skrabucha, Andrzej Dyduszynski, Jerzy Kuch, Edmund Nartowicz, Grazyna Swiatecka, David F. Kong, Christopher B. Granger

    Résumé Résumé Plan Plan  
• • ·Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials

    Page :799-805

    John H. Alexander, Christopher B. Granger, Zygmunt Sadowski, Philip E. Aylward, Harvey D. White, Trevor D. Thompson, Robert M. Califf, Eric J. Topol, For the GUSTO-I and GUSTO-IIb Investigators

    Résumé Résumé Plan Plan  
• • ·Coronary calcium: The good, the bad, and the uncertain

    Page :806-814

    Terence M. Doherty, Robert C. Detrano, Susanne L. Mautner, Gisela C. Mautner, Robert M. Shavelle

    Résumé Résumé Plan Plan  
• • ·Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina

    Page :815-820

    Hakim Benamer, Philippe Gabriel Steg, Joelle Benessiano, Eric Vicaut, Cedric J. Gaultier, Pierre Aubry, Olivier Boudvillain, Laurent Sarfati, Eric Brochet, Laurent J. Feldman, Dominique Himbert, Jean-Michel Juliard, Patrick Assayag

    Résumé Résumé Plan Plan
• • ·Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction

    Page :821-829

    Marie Gardtman, Mikael Dellborg, Christian Brunnhage, Jonny Lindkvist, Lisbeth Waagstein, Johan Herlitz

    Résumé Résumé Plan Plan  
• • ·Disparate effects of the 1989 Loma Prieta and 1994 Northridge earthquakes on hospital admissions for acute myocardial infarction: Importance of superimposition of triggers

    Page :830-836

    David L. Brown

    Résumé Résumé Plan Plan  
• • ·How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts

    Page :837-845

    Youlian Liao, Daniel L. McGee, Richard S. Cooper, Mary Beth E. Sutkowski

    Résumé Résumé Plan Plan  
• • ·Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction

    Page :846-853

    Ton J.M. Oude Ophuis, Frits W. Bär, Frank Vermeer, Ruud Krijne, Ward Jansen, Hans de Swart, Vincent van Ommen, Chris de Zwaan, Domien Engelen, Willem R. Dassen, Hein J.J. Wellens

    Résumé Résumé Plan Plan  
• • ·Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: A multicenter parallel group study

    Page :854-862

    Håkan Emanuelsson, Kenneth Egstrup, Kjell Nikus, Jan Ellström, Torben Glud, Cornel Pater, Morten Scheibel, Anders Tisell, Karl-Johan Tötterman, Mikael Forsby, For the TRAFFIC Study Group

    Résumé Résumé Plan Plan  
• • ·Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction

    Page :863-869

    Ernest L. Fallen, Geoff Coates, Claude Nahmias, Raman Chirakal, Rob Beanlands, Lindi Wahl, Gwen Woodcock, Margo Thomson, Markad Kamath

    Résumé Résumé Plan Plan  
• • ·The high cost of syncope: Cost implications of a new insertable loop recorder in the investigation of recurrent syncope

    Page :870-877

    Andrew D. Krahn, George J. Klein, Raymond Yee, Ven Manda^b

    Résumé Résumé Plan Plan  
• • ·Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial

    Page :878-886

    Brian Olshansky, Elizabeth A. Hahn, Vernon L. Hartz, Stephen P. Prater, Jay W. Mason, The ESVEM Investigators

    Résumé Résumé Plan Plan  
• • ·High-dose enoximone to evaluate reversibility of pulmonary hypertension: Is there a diagnostic value of neurohormonal measurements?

    Page :887-894

    Olaf Schulz, Veselin Mitrovic, Markus Schönburg, Jochen Thormann

    Résumé Résumé Plan Plan  
• • ·Cardioprotection for Duchenne’s muscular dystrophy

    Page :895-902

    Yuka Ishikawa, John R. Bach, Ryoji Minami

    Résumé Résumé Plan Plan  
• • ·Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study

    Page :903-909

    Michael S. Lauer, Martin G. Larson, Jane C. Evans, Daniel Levy

    Résumé Résumé Plan Plan  
• • ·Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction

    Page :910-918

    Steen H. Poulsen, Svend E. Jensen, Kenneth Egstrup

    Résumé Résumé Plan Plan  
• • ·Congestive heart failure hospitalizations and survival in California: Patterns according to race/ethnicity

    Page :919-927

    Mark Alexander, Kevin Grumbach, Linda Remy, Richard Rowell, Barry M. Massie

    Résumé Résumé Plan Plan  
• • ·Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers

    Page :928-931

    Joseph A. Istvan, Wondra Wong Lee, A.Sonia Buist, John E. Connett

    Résumé Résumé Plan Plan
• • ·Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: Utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army personnel

    Page :932-941

    Patrick G. O’Malley, Allen J. Taylor, Robert V. Gibbons, Irwin M. Feuerstein, David L. Jones, Marina Vernalis, Michael Brazaitis

    Résumé Résumé Plan Plan  
• • ·Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous dipyridamole thallium-201 imaging

    Page :942-948

    Daniel J. Lenihan, Abbe F. Rosenbaum, Peggy Burwinkel, Chih-Yu Tseng, Geetha Bhat, Lynne Wagoner, Richard A. Walsh, Myron C. Gerson

    Résumé Résumé Plan Plan
• • ·Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus

    Page :949-957

    Xingping Kang, Daniel S. Berman, Howard Lewin, Romalisa Miranda, Jacob Erel, John D. Friedman, Aman M. Amanullah

    Résumé Résumé Plan Plan  
• • ·Real-time, three-dimensional echocardiography: Feasibility of dynamic right ventricular volume measurement with saline contrast

    Page :958-966

    Takahiro Ota, Craig E. Fleishman, Mike Strub, George Stetten, Chikai J. Ohazama, Olaf T. von Ramm, Joseph Kisslo

    Résumé Résumé Plan Plan  
• • ·Determinants of aortic artifacts during transesophageal echocardiography of the ascending aorta

    Page :967-972

    Maria Angela Losi, Sandro Betocchi, Carlo Briguori, Fiore Manganelli, Quirino Ciampi, Leonardo Pace, Gabriele Iannelli, Nicola Spampinato, Massimo Chiariello

    Résumé Résumé Plan Plan  
• • ·Echocardiographic evaluation of patients with primary antiphospholipid syndrome

    Page :973-978

    Nilda Espínola-Zavaleta, Jesús Vargas-Barrón, Terry Colmenares-Galvis, Flory Cruz-Cruz, Angel Romero-Cárdenas, Candace Keirns, Mary-Carmen Amigo

    Résumé Résumé Plan Plan  
• • ·Evaluating the economic implications of cardiovascular therapeutics

    Page :S35

    Robert M. Califf

    
• • ·Fundamentals of economic analysis

    Page :S38

    Daniel B. Mark, Tracey A. Simons

    Plan Plan  
• • ·Role of economic models in randomized clinical trials

    Page :S41

    Mark A. Hlatky

    Plan Plan
• • ·Statistical issues in cost-effectiveness analysis

    Page :S47

    Elizabeth R. DeLong, Tracey Simons

    Plan Plan  
• • ·Terminology I would like to see disappear

    Page :S51

    Allan S. Detsky

    Plan Plan
• • ·A survey of standards and guidelines for cost-effectiveness analysis in health care*

    Page :S53

    Alan Stewart, Jordana K. Schmier, Bryan R. Luce

    Plan Plan
• • ·What constitutes a useful health economic study for the pharmaceutical industry?

    Page :S62

    Jean Paul Gagnon

    Plan Plan
• • ·What constitutes a useful economic study? The health systems perspective

    Page :S67

    Thomas H. Lee

    Plan Plan
• • ·Consortium perspective: What constitutes a useful economic study?

    Page :S71

    Connie Chen, Peter H. Vlasses

    Plan Plan
• • ·Role of government agencies regarding cost-effectiveness claims: FDA perspective

    Page :S75

    Robert Temple

    Plan Plan
• • ·Product labeling and pharmacoeconomic information

    Page :S78

    Louis A. Morris

    Plan Plan
• • ·The value of cost-effectiveness analyses for reimbursement decisions: Perspectives from Medicare

    Page :S81

    Steven H. Sheingold

    Plan Plan
• • ·Thrombolytic therapy: Economic considerations

    Page :S87

    Harlan M. Krumholz

    Plan Plan
• • ·The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy

    Page :S90

    Robert M. Califf, David Stump, Eric J. Topol, Daniel B. Mark

    Plan Plan  
• • ·Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: A health system perspective on thrombolytic therapy for acute myocardial infarction

    Page :S94

    Christopher A. Lewandowski, John Kahler

    Plan Plan
• • ·Comparative economic data regarding lipid-lowering drugs

    Page :S97

    J.Sanford Schwartz

    Plan Plan
• • ·Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: Lipid-lowering therapies — an industry perspective

    Page :S105

    Joseph D. Jackson

    Plan Plan
• • ·Lipid-lowering drugs, cost-effectiveness data, and the formulary system: A health systems perspective

    Page :S111

    John M. Kessler

    Plan Plan
• • ·ACE inhibitors in the management of congestive heart failure: Comparative economic data

    Page :S115

    William L. Boyko, Henry A. Glick, Kevin A. Schulman

    Plan Plan
• • ·Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: A pharmaceutical industry perspective

    Page :S120

    Stephen J. Boccuzzi

    Plan Plan  
• • ·Use of abciximab: Comparative economic data

    Page :S123

    Daniel B. Mark, Tracey A. Simons

    Plan Plan  
• • ·Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy

    Page :S126

    John J. Schrogie

    Plan Plan
• • ·An industry perspective on health economics studies

    Page :S129

    Keaven M. Anderson, Mohan V. Bala, Harlan F. Weisman

    Plan Plan
• • ·Evaluation of the cost-effectiveness of coronary stenting: A societal perspective

    Page :S133

    David J. Cohen

    Plan Plan  
• • ·Coronary stents: An industry perspective

    Page :S138

    Paul R. Marshall

    Plan Plan
• • ·Coronary stents: A health system perspective

    Page :S142

    Muzaffar Ahmad

    Plan Plan